The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.
 
Wakako Daido
No Relationships to Disclose
 
Takeshi Masuda
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin International; Kyowa Kirin International; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD K.K
 
Nobuki Imano
No Relationships to Disclose
 
Naoko Matsumoto
No Relationships to Disclose
 
Hiroyasu Shoda
No Relationships to Disclose
 
Kosuke Hamai
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical
 
Yasuo Iwamoto
No Relationships to Disclose
 
Yusuke Takayama
No Relationships to Disclose
 
Shohei Mishima
No Relationships to Disclose
 
Ken Masuda
No Relationships to Disclose
 
Shigeo Kawase
No Relationships to Disclose
 
Yoshikazu Awaya
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Sanofi
 
Yoshifumi Nishimura
No Relationships to Disclose
 
Naoki Shiota
No Relationships to Disclose
 
Nobuhisa Ishikawa
Speakers' Bureau - Boehringer Ingelheim
 
Masahiro Yamasaki
Honoraria - AstraZeneca Japan; Chugai Pharma; MSD; Ono Pharmaceutical
 
Soichi Kitaguchi
No Relationships to Disclose
 
Kazunori Fujitaka
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yasushi Nagata
No Relationships to Disclose
 
Noboru Hattori
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD; Taiho Pharmaceutical